News & Updates

First-line treatment with carboplatin/paclitaxel (CP), with or without radiotherapy, is not associated with improvements in survival among patients with anaplastic thyroid cancer (ATC), as shown in a study.

Tambotatug pelitecan (Tam-Peli), a novel B7-H3–targeting antibody–drug conjugate, delivers significant survival boost in relapsed small-cell lung cancer (SCLC) as compared with topotecan, according to the phase III TAISHAN-302 trial.

Results from the Italian RISP* trial presented at WCLC 2026 show improvement in smoking cessation rates following treatment with cytisine, a partial agonist of α4β2nicotinic acetylcholine receptors.

In the first-line treatment of patients with advanced HER2-mutant non-small cell lung cancer (NSCLC), trastuzumab deruxtecan (T-DXd) monotherapy confers a 6-month improvement in progression-free survival (PFS) compared with pembrolizumab plus chemotherapy, as shown in the phase III DESTINY-Lung04 trial.

Patients with chronic hepatitis B (CHB) infection who consume high levels of alcohol are at increased risk of hepatocellular carcinoma (HCC), as suggested in a retrospective study from China.

A report from Children’s Oncology Group (COG) AALL1731 study showed that paediatric patients with standard-risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL) with undetectable minimal residual disease (MRD) at end of induction (EOI) by flow cytometry (FC) but not high-throughput sequencing (HTS) had inferior outcomes on chemotherapy alone, which were partially but not entirely mitigated by blinatumomab. In addition, outcomes of chemotherapy-only treatment among patients with MRD by HTS were not superior to those of patients with detectable MRD.

Some biomarkers of one-carbon metabolism are associated with toxicities induced by chemotherapy in patients with stage II‒III colorectal cancer (CRC), suggests a study.

A 74-year-old nonsmoker and non­drinker presented to a private urologist in January 2025 with gross haematu­ria. Aside from benign prostatic hyper­plasia, he was well and physically fit. On 14 January 2025, a CT scan re­vealed a large mass measuring 5.8 cm with full-thickness infiltration into the bladder wall, consistent with clinical T3 disease. A metastatic lymph node (LN) of approximately 1.0 cm was not­ed in the left internal iliac region, with no distant metastases. 

Replacing two cycles of highly toxic, high-dose combination chemotherapy with two cycles of blinatumomab as first-line (1L) treatment significantly improves outcomes including 4-year event-free survival (EFS) and reduces adverse events (AEs) in paediatric patients with high-risk B-cell acute lymphoblastic leukaemia (B-ALL), results of the phase III AIEOP-BFM 2017 trial have shown.